Our experimental approach in the last few years has suggested that EVOO-related anti-breast cancer actions mainly affect the occurrence, the aggressive behavior and the therapeutic management of HER2 oncogene-driven breast carcinomas. Here, ERBB2 is linked to breast carcinoma.